Filing Details

Accession Number:
0001415889-22-010986
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-02 16:04:32
Reporting Period:
2022-11-01
Accepted Time:
2022-11-02 16:04:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802665 Harmony Biosciences Holdings Inc. HRMY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1615993 M. Jeffrey Dayno C/O Harmony Biosciences Holdings, Inc.
630 W Germantown Pike, Suite 215
Plymouth Meeting PA 19462
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-01 15,000 $8.22 15,000 No 4 M Direct
Common Stock Disposition 2022-11-01 15,000 $55.10 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2022-11-01 15,000 $0.00 15,000 $8.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,470 2027-11-13 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.62. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The stock option vests in five equal annual installments beginning on November 1, 2018.
  4. The Form 4 filed by the reporting person on October 20, 2021, understated the number of securities owned following the reported transaction by 1 share. The amount of securities reported herein reflects the correct number of securities owned following the transactions reported on this Form 4.